Bioceres Q3 2025 Earnings Report
Key Takeaways
Bioceres delivered a net loss of $1.6 million in Q3 2025 on revenues of $60.6 million, down from $84 million a year ago. The decline was mainly due to the absence of the Syngenta downpayment recorded in the prior year. Nevertheless, operating cash flow improved significantly to $23.3 million, supported by better working capital management.
Revenue declined to $60.6 million due to the absence of last year's Syngenta downpayment.
Net loss was $1.6 million, reversing a profit of $9.8 million in Q3 2024.
Cash flow from operations surged to $23.3 million, driven by improved inventory and receivables management.
EPA registration of Rinotec positions the company for growth in biological crop protection.
Bioceres
Bioceres
Bioceres Revenue by Segment
Forward Guidance
Bioceres is positioning itself for future growth by streamlining operations and advancing its biological solutions portfolio, despite current seasonal and macroeconomic headwinds.
Positive Outlook
- EPA approval of Rinotec expands biological solutions portfolio.
- Improved working capital management boosting cash flow.
- Reduced operating expenses through seed business restructuring.
- Expanded geographic rights and lowered royalty obligations via IP exchanges.
- Well positioned to leverage innovation in biological inputs.
Challenges Ahead
- Revenue decline due to non-recurring Syngenta payment in prior year.
- Seasonal slowdown in core geographies like Argentina.
- Gross margin dropped from 51% to 39%.
- Net income turned negative despite positive operating income.
- Decline in Adjusted EBITDA due to lower gross profit.
Revenue & Expenses
Visualization of income flow from segment revenue to net income